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Background.During times of organ scarcity and extended use of liver grafts, protective strategies in transplantation are gaining
importance. We demonstrated in the past that volatile anesthetics such as sevoflurane attenuate ischemia-reperfusion
injury during liver resection. In this randomized study, we examined if volatile anesthetics have an effect on acute graft injury and
clinical outcomes after liver transplantation. Methods. Cadaveric liver transplant recipients were enrolled from January 2009
to September 2012 at 3 University Centers (Zurich/Sao Paulo/Ghent). Recipients were randomly assigned to propofol (control
group) or sevoflurane anesthesia. Postoperative peak of aspartate transaminase was defined as primary endpoint, secondary
endpoints were early allograft dysfunction, in-hospital complications, intensive care unit, and hospital stay. Results. Ninety-
eight recipients were randomized to propofol (n = 48) or sevoflurane (n = 50). Median peak aspartate transaminase after transplan-
tation was 925 (interquartile range, 512–3274) in the propofol and 1097 (interquartile range, 540–2633) in the sevoflurane group.
In the propofol arm, 11 patients (23%) experienced early allograft dysfunction, 7 (14%) in the sevoflurane one (odds ratio, 0.64
(0.20 to 2.02, P = 0.45). There were 4 mortalities (8.3%) in the propofol and 2 (4.0%) in the sevoflurane group. Overall and major
complication rates were not different. An effect on clinical outcomes was observed favoring the sevoflurane group (less severe
complications), but without significance. Conclusions. This first multicenter trial comparing propofol with sevoflurane anesthe-
sia in liver transplantation shows no difference in biochemical markers of acute organ injury and clinical outcomes between the
2 regimens. Sevoflurane has no significant added beneficial effect on ischemia-reperfusion injury compared to propofol.
(Transplantation 2015;99: 1606–1612)
L iver transplantation is a well-established treatment op-tion for end-stage liver disease and acute liver failure. Modification of surgical techniques, immunosuppressiveregimen, and preservation solutions, as well as a better un-
derstanding of the use of marginal donors and recipients have
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led to improved short- and long-term survivals.1-7 It is well
known that severity of hepatic ischemia-reperfusion injury
also determines postoperative organ function and long-term
graft survival.8,9
Numerous strategies to protect livers from ischemia-
reperfusion injury have been proposed, but only very few
found their way into clinical practice. Anesthesiological pro-
tocols for liver transplantation differ between centers and
guidelines exist; however, level 1 evidence is rare. Recently, the
effect of volatile anesthetics, such as sevoflurane or desflurane,
versus intravenous anesthesia using propofol was found to
mitigate ischemia-reperfusion injury during liver resections
in randomized studies.10-13 The cytoprotective effect of vol-
atile anesthetics may either be initiated before the onset of
ischemic injury (preconditioning), immediately on reperfu-
sion (postconditioning), or for the entire surgical procedure
(conditioning). Both preconditioning and postconditioning
with volatile anesthetics reduced liver cell injury and com-
plications after liver resection in our center.11,13 Other groups
have corroborated these findings, such as Balzan et al.14
We therefore asked, if the use of volatile anesthetics might
have an impact on outcomes after liver transplantation, which
undoubtedly represents one of the most complex forms of
ischemia-reperfusion injury to the liver.
This multicenter randomized clinical trial has a superiority
trial design to prove that sevoflurane is better than propofol
anesthesia in liver transplant recipients. We hypothesized
that sevoflurane attenuates ischemia-reperfusion injury, mea-
sured by postoperative peak value of aspartate transaminase
(AST) as primary endpoint, and also decreases the number of
postoperative complications, defined as secondary endpoint.
METHODS
Study Design
This multicenter randomized controlled trial (RCT) was
conducted in 3 well-established liver transplant centers: the
University Hospital Zurich, Zurich, Switzerland, the Hos-
pital das Clinicas, University of Sao Paulo School of Medi-
cine, Sao Paulo, Brazil, and the Ghent University Hospital,
Ghent, Belgium.
Patients enrolled in the study were randomly assigned to
liver transplantation with either the intravenous anesthetic
propofol (control group) or the volatile anesthetic sevoflurane
(conditioning group). The aim of the trial was to test the
hypothesis that conditioning with sevoflurane leads to better
clinical outcomes as compared to the control group. This
trial was approved by the institutional boards for human
studies of the 3 centers (principal investigator and sponsor
located at the University Hospital Zurich, protocol Nr. StV
15–2008; Swissmedic notification 2008DR4348), registered
at ClinicalTrial.gov NCT00913276, and is reported accord-
ing to the CONSORT statement.15
Study Population
Patients were assessed for eligibility between January 2009
and September 2012. Eligible participants were all adults
(≥18 years) admitted for liver transplantation, who spoke
the local language of the referred center and were able to
provide written informed consent. Exclusion criteria were
known or suspected allergy to propofol, soy, or egg, car-
diovascular instability with norepinephrine infusion above
15 μg per minute before induction of anesthesia and severe
impairment of renal and/or pulmonary function (e.g., dialy-
sis, hemofiltration, FiO2 > 0.5) before liver transplantation.
Patients already included in another study were also excluded.
Patients receiving organs from living donors as well as patients
undergoing partial organ transplantation were not included.
Anesthesia
Anesthesia was performed in all 3 centers by a group of
dedicated transplantation anesthesiologists. To maintain
an optimal hemodynamic, patients were monitored with
Swan-Ganz as well as with arterial and central venous cath-
eters following respective departmental guidelines in each center.
Anesthesia was induced in both groups identically as
follows: suppression of laryngoscopic stress response was
achieved with intravenous application of fentanyl 3 μg/kg
or the initiation of remifentanil infusion. Hypnosis was
started with target control infusion of propofol set to effect
site concentrations between 3 and 6 μg/mL, using program-
mable perfusors and the Schnider data set algorithm (Alaris
PK, Cardinal Health, Dublin OH). Atracurium 0.5 mg/kg
was applied to facilitate endotracheal intubation. In the set-
ting of a rapid sequence induction, higher targets of propofol
(5-7 μg/mL) and rocuronium (0.9 mg/kg) were chosen.
In the propofol group (control), anesthesia was main-
tained using propofol target control infusion as described
above to obtain bispectral index values between 40 and 60
throughout the whole procedure (Covidien, Mansfield, MA).
This method is used to monitor depth of anesthesia, measur-
ing the effects of anesthetics and sedatives on the brain, which
is based on an algorithmic analysis of the patient's electro-
encephalogram. Analgesia was achieved by applying boluses
of fentanyl 1 to 2 μg/kg and/or continuous infusion of
remifentanil up to 20 μg/kg/h according to the need of the pa-
tient. Muscle relaxation was monitored with train of four
stimulation of the left ulnar nerve.When train of four response
was 2 or more, atracurium 5-10 mg was applied. In the
sevoflurane group, however, propofol infusion was stopped
immediately after induction and replaced by sevoflurane
0.6 to 1.5 minimum alveolar concentration supplemented
with fentanyl, remifentanil, and atracurium as described for
the propofol group targeting the same bispectral index
values. Therefore, according to a common definition estab-
lished for cardiac surgery,16,17 the recipient experienced a
conditioning with sevoflurane through the entire procedure,
the transplanted liver itself a postconditioning. All patients
were routinely admitted to the intensive care unit (ICU)
intubated, and no immediate extubation was performed at
the end of surgery. For the conditioning group, after termi-
nation of the surgical procedure, sevoflurane application
was stopped, and propofol infusion reinstalled to maintain
sedation for the transfer to the ICU.
Surgery
Deceased donor liver transplantation was performed by
dedicated teams of liver transplantation surgeons using com-
monly used preservation fluids for organ procurement in-
cluding UW, HDK, and Celsior. The operative procedure
was performed using both caval replacement and Piggyback
technique. Reperfusion of the liver started with opening of
the portal vein, followed by opening of the artery. After
arterial reperfusion, the bile duct was connected either to
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the recipients' bile duct (choledocho-choledochostomy) or to
a small-bowel loop (hepatico-jejunostomy). A back table bi-
opsy of the donor liver was performed before implantation.
Outcomes
The primary endpoint was the peak value of AST after
transplantation up to day 7, representing a frequently used
marker for ischemia-reperfusion injury.13,18,19 Secondary
endpoints included postoperative peak alanine transaminase
(ALT), early allograft dysfunction (EAD), postoperative com-
plications assessed according to the Clavien-Dindo complica-
tion score,20 and duration of ICU and hospital stay.
Data Collection
A standardized data sheet was used in all 3 centers to
collect the data of donors and recipients. The recipient-
specific physical status was assessed according to the
American Society of Anesthesiologists classification, the se-
verity of liver disease based on the model for end-stage liver
disease (MELD), international normalized ratio (INR), total
bilirubin. and creatinine on admission.21 Expected liver
weight was calculated using the formula of Urata et al22
and Lemke et al23 to elucidate the possible mismatch be-
tween actual and expected graft weight. Cold ischemia time
was defined as the time between aortic cross clamping in the
donor until removal of the liver from ice, warm ischemia time
as the time of removal from ice until portal vein reperfusion.
Liver-specific biochemical variables, such as AST, ALT,
total bilirubin, alkaline phosphatase activity, and prothrom-
bin time (Quick; INR) were recorded at standard timepoints:
preoperatively (for donor and recipient) as well as postoper-
atively after 6 hours, on days 1, 3, 5, and 7. A validated def-
inition of EAD was used: Quick value ≤41% (INR ≥1.6),
and/or ALT >2000 U/I and/or bilirubin ≥171 μmol/l
(≥10 mg/dl) at day 7 after liver transplantation.24,25 Com-
plications were assessed during hospitalization, using the
Clavien-Dindo classification with grade 0 (no complication)
to grade V (death).20 Complications grade IIIb or higher
were defined as “major complications” because they require
management under general anesthesia.
Donor liver histology was evaluated routinely, but parti-
cularly for the occurrence of macrosteatosis (< or ≥30%) on
frozen or formalin-fixed, paraffin-embedded biopsies stained
with hematoxylin-eosin.13
Postoperative data and outcome were collected by coin-
vestigators in all 3 centers, blinded for the treatment of
the patients.
Sample Size
We used previous trial data on transaminase levels after
liver transplantation to estimate the mean postoperative peak
AST level (primary outcome) without conditioning (mean of
1000 U/L) and its variability (standard deviation 300 U/L).26
A sample size of 48 patients in each group showed a differ-
ence of 20% (or 200 U/L, respectively) in mean postoperative
peak AST levels between the groups of normal and steatotic
livers. We assumed a standard deviation of 300 U/L and chose
a power of 90% at a significance level of 5% (2-sided). We
defined these values as clinically relevant based on previous
results in liver protection.27 With an expected dropout rate
of 10% (e.g., patients randomized but not undergoing liver
transplantation), the total minimal sample size increased to
106 patients.
Randomization
A web-based computerized and central randomization
service was used for the allocation of the participants
(www.randomizer.at) with prestratification for center. The
patients were randomized after admission to the hospital
and blinded to the treatment group.
Statistical Analysis
We analyzed all patients in an intent-to-treat manner. To
compare the postoperative outcomes between the propofol
and sevoflurane group, we used linear regression analysis
for continuous outcomes (e.g., transaminases), logistic regres-
sion analysis for binary outcomes (e.g., EAD), and ordered
logistic regression analysis for ordinal outcomes (Clavien-
Dindo complication index20), always with group allocation
as independent variable. For continuous outcomes, descrip-
tive results are presented as medians (interquartile range,
IQR), and the results from the linear regression analyses
are presented as the mean difference (with 95% confidence
interval, CI). For binary outcomes, we present the absolute
numbers of events (proportion in %) in the first columns
and the results from the logistic and ordered logistic regres-
sion analyses as odds ratio with 95% CI. We adjusted all
analyses using a multivariate analysis for center as well as
for age and sex of the recipients (results not shown) due to
a slight imbalance between groups with regard to age and
sex (Table 1). Transformation of continuous variables was
tested, but the assumptions of linear regression (normality
and homoscedasticity of residuals) were met similarly, as
TABLE 1.
Baseline characteristics of donors and recipients
Propofol Sevoflurane
Donors 48 50
Age: median (IQR), y 55 (38-65) 48 (41-59)
Sex: male (%) 25 (52) 29 (59)
AST: median (IQR), U/L 58.5 (26-162.5) 56.5 (27.5-134)
ALT: median (IQR), U/L 41.5 (24-125.5) 46.5 (17.5-85)
Bilirubin: median (IQR), μmol/L 5.6 (0.5-11.5) 9.0 (2.7-10.9)
Liver weight: median (IQR), g 1440 (1253-1769) 1497 (1292-1782)
Macrosteatosis≥ 30%: number (%) 2 (4) 3 (6)
CVA as cause of brain death: number (%) 23 (49) 23 (47)
Recipients 48 50
Age: median (IQR), y 53 (37-61) 58 (51-64)
Sex: male (%) 41 (85) 33 (66)
ASA: median (IQR) III (III-IV) III (III-IV)
MELD: median (IQR) 19 (11-24) 17 (10-27)
Primary indication for TPL, number (%)
ESLD (cirrhosis) 29 (60%) 25 (48%)
Tumor (HCC) 10 (21%) 14 (28%)
Other 9 (19%) 12 (24%)
Baseline AST: median (IQR), U/L 60 (42-94) 64 (37-134)
Baseline ALT: median (IQR), U/L 41 (28-72) 49 (25-89)
Bilirubin: median (IQR), μmol/L 43 (16-87) 40 (14-110)
APh: median (IQR), U/L 129 (96-224) 120 (86-171)
Quick: % (IQR) 60 (41-78) 54 (40-77)
Liver weight mismatch: % (IQR) 0.98 (0.76-1.18) 1.05 (0.79-1.20)
Mismatch: expected liver weight calculated using the formula of Urata et al.22 and Lemke et al.23
ASA, American Society of Anesthesiologists; APh, alkaline phosphatase; CVA, cerebrovascular accident;
ESLD, end-stage liver disease; HCC, hepatocellular carcinoma; TPL, transplantation.
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compared to the analyses with untransformed variables, and
the results remained essentially the same. To compare trans-
aminases between groups, from baseline measurements (pre-
operative day) to 7 postoperative days, a random effects
model was used that took the correlated structure of repeated
measurements into consideration (xtreg command of STATA).
Interquartile range was 25 to 75 percentile. P values, 2-tailed,
less than 0.05 were defined as statistically significant. All
analyses were conducted using STATA (STATA forWindows,
version 10.2, Stata Corp; College Station, TX).
RESULTS
Patients
Figure 1 illustrates in detail the patient flow from the
screening of potential participants to the final assessment.
During the study period, 343 patients were assessed for
eligibility, 112 were randomized with 72 in Zurich, 26 in
Sao Paulo, and 14 in Ghent. Fourteen patients dropped out
because they did not receive a transplant after randomization
on admission. Ninety-eight patients were finally included in
the study, 50 in the sevoflurane and 48 in the control (propo-
fol) group (66 in Zurich, 22 in Sao Paulo and 10 in Ghent).
Decisions to change the allocated procedure were based
on the anesthesiologists concerns for the safety of the patient.
One patient in the propofol group crossed to volatile anes-
thesia, and one patient of the propofol group received
sevoflurane due to cardiovascular instability during anes-
thesia. Sevoflurane was additionally applied to another pa-
tient in the propofol group due to insufficient hypnosis with
propofol as single anesthetic. Patients' data were analyzed
in the original group to which they were randomly assigned
(intent to treat).
Baseline characteristics of the 2 study groups were well
matched, as presented in Table 1. Donor characteristics were
similar with regard to age, sex, AST, ALT, bilirubin, and liver
weight. Macrosteatosis 30% or higher was found in only
5 grafts (2 in the propofol and 3 in the sevoflurane group).
Most livers were procured from donors after brain death,
2 livers from donors after cardiac death (1 in each group).
Cerebrovascular accident was the most frequent reason
for brain death donors with 23 (49%) in the propofol and
23 (47%) in the sevoflurane group.
With regard to recipient characteristics, no difference be-
tween groups was observed for the American Society of
Anesthesiologists physical status classification, laboratory
MELD score, indications for transplantation (hepatitis C
and retransplantation included), as well as baseline values
of hepatic biochemical markers. Also, transplanted liver
volume in relation to recipient's body weight was compara-
ble in both groups. There was a slight difference in age with
a median of 53 years (IQR, 37-61 years) in the propofol
and 58 years (IQR, 51-64 years) in the sevoflurane arm, as
well as sex with 41 (85%) men in the propofol and 33 (66%)
in the sevoflurane group.
We adjusted all analyses using a multivariate analysis
for center as well as for age and sex of the recipients due to
a slight imbalance between groups with regard to age and
sex (Table 1).
Intraoperative Data
The median cold ischemia time was comparable in both
groups (414 minutes, IQR, 350-585 minutes in the propofol
and 455 minutes, IQR, 352-553 minutes in the sevoflurane
group) (Table 2). Also, warm ischemia time was similar in
both groups with a median of 54 minutes (IQR, 40-65 min)
for propofol, and 54 min (IQR, 42-68 min) for sevoflurane
patients. Operating time and transfusion of blood products
were comparable. Patient's hemodynamic was controlled
based on institutional protocols aiming at an optimal perfu-
sion of the organs. No “significant” reperfusion syndrome
was described.
FIGURE 1. Enrollment and randomization of patients.
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Biochemical Endpoints
The primary endpoint of the study, the median postop-
erative peak value of AST, was similar in both groups with
a median of 925 U/L (IQR, 512-3274 U/L) and 1097 U/l
(IQR, 540-2633 U/L) in the propofol and the sevoflurane
group, respectively, with an adjusted mean difference of
215 U/L (95% CI, −1017 to 1448 U/L, P = 0.73)
(Table 3). Without adjustment for age and sex, the results
were a mean difference of 196 U/L (95% CI, −964 to
1356 U/L; P = 0.74).
The secondary endpoint, median peak value of ALT, was
similar in both groups with 781 U/L (IQR, 405-2063 U/L)
in the propofol and 711 U/L (IQR, 424-1645 U/L) in the
sevoflurane group. Mean difference was −162 U/L (95%
CI, −722 to 399 U/L; P = 0.57) (without adjustment for age
and sex: −114 U/L (95% CI, −640 to 411 U/L, P = 0.67).
The lack of difference between groups was also supported
by evaluating repeated AST und ALT measurements start-
ing at the 1st and ending at the 7th postoperative day. For
AST, the mean difference between the 2 groups over 7 days
was 49 U/L (95% CI, −348 to 445 U/L; P = 0.81), for ALT
4 U/L 4 (95% CI, −256 to 263 U/L; P = 0.98). Considering
the fact that the size of the transplanted liver might have
had impact on the release of transaminases, AST values
were recalculated in correlation to the liver weight. Also,
these results showed no significant difference between both
groups (Table 3).
No difference between groupswith regard to other postop-
eratively determined biochemical markers, such as bilirubin,
alkaline phosphatase, and Quick, were observed (Table 3).
Early allograft dysfunction as defined at day 7 occurred
in 7 patients (14%) in the sevoflurane group compared to
11 (23%) in the propofol group (odds ratio, 0.64; 95% CI,
0.20 to 2.02, P = 0.45) (Table 4).
Clinical Outcome
Hospital mortality was 4 of 48 patients (8.3%) in the
propofol and 2 of 50 patients (4.0%) in the sevoflurane
group. Overall morbidity rate was not significantly different
between the groups (odds ratio, 0.66; 95% CI, 0.24 to 1.81,
P = 0.42) (Table 4). Major complications (grade IIIb-V) were
not different between groups (50% vs 40% for propofol vs
the sevofluorane group (odds ratio, 0.58; 95% CI, 0.24 to
1.41; P = 0.23). Severity of complications between groups
showed an effect in favor of the sevofluorane group, but
were not significantly different with a median of grade ll
complications (IQR, 0-IIIb) in the sevoflurane compared to
median of grade IIIa (IQR, II-IVb) in the propofol group
(odds ratio, 0.51; 95% CI, 0.24 to 1.09; P = 0.08). Clini-
cally relevant outcome variables, such as ICU stay (median
of 4 days in both groups with a mean difference of −1 day,
95% CI, −4 to 2 days, P = 0.64), as well as length of hospital
stay (median of 18 days in the sevoflurane compared to 21 days
in the propofol group, mean difference of −1 day; 95% CI, −8
to 6 days; P = 0.77) were not significantly different.
DISCUSSION
This is the first multicenter RCT, which evaluates whe-
ther application of sevoflurane in patients undergoing liver
transplantation reduces postoperative ischemia-reperfusion
injury and has an impact on clinical outcome. In our trial set-
ting, sevoflurane has no benefit over a propofol-based regi-
men in liver transplantation.
Testing of variants of clinical management in transplant
anesthesia in the form of randomized clinical trials has been
rare and we therefore consider it important to report our
negative finding in a trial that has been performed using
“state-of-the-art” methodology.
The main limitation of this trial is the choice of a surrogate
marker as the primary endpoint instead of a clinical outcome
parameter. Although the release of liver enzymes are ac-
cepted biochemical markers for acute organ injury after
transplantation and has been used in many other RCTs,28
they represent markers of unknown significance for the
clinician. Clinical outcome should therefore be preferred as
TABLE 2.
Intraoperative parameters for the propofol and sevoflurane group
Propofol
(n = 48)
Sevoflurane
(n = 50)
Cold ischemia time: median (IQR), min 414 (350-585) 455 (352-553)
Warm ischemia time: median (IQR), min 54 (40-65) 54 (42-68)
Red blood cells received: n (%) a
median (IQR) if received
26 (70) 25 (64)
4 (2-8) 6 (2-10)
Frozen plasma received: n (%) a
median (IQR) if received
9 (24) 8 (21)
4 (4-8) 10 (7-27)
Platelets received: n (%)a
median (IQR) if received)
16 (43) 15 (39)
2 (1-2) 1 (1-4)
a Data missing for 22 patients.
TABLE 3.
Comparison of postoperative biochemical outcomes for propofol and sevoflurane group
Propofol Sevoflurane Mean difference (95% CI), Pa
Peak AST: median (IQR), U/L) 925 (512-3274) 1097 (540-2633) 215 (−1017 to 1448), 0.73
Peak ALT: median (IQR), U/L 781 (405-2063) 711 (424-1645) −162 (−722 to 399), 0.57
Peak AST (in relation to g liver weight): median (IQR), U/L ⋅g 0.76 (0.43-1.99) 0.69 (0.41-1.76) 0.14 (−0.58-0.86), 0.70
AST: repeated measurements from days 1 to 7, U/L 49b (−348 to 445), 0.81
ALT: repeated measurements from days 1 to 7, U/L 4b (−256 to 263), 0.98
AST (in relation to g liver weight): Repeated measurements from days 1 to 7, U/L ⋅g 0.03 (−0.28-0.35), 0.84
Bilirubin: repeated measurements from days 1 to 7, μmol/L 3b (−23 to 30), 0.81
APh: repeated measurements from days 1 to 7, U/L 18b (−18 to 54), 0.33
Quick: repeated measurements from days 1 to 7, % −2b (−7 to 4), 0.50
a All comparisons are adjusted for center and age and sex of recipient.
b Difference is mean difference between groups over days 1 to 7.
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primary endpoint for trials,29 but there remains the limitation
that an appropriate sample size can rarely be obtained even
in multicenter collaboration without extending the time
frame beyond practicability. We decided to evaluate a fre-
quently used marker like AST to achieve closure of the trial
within a reasonable time frame. Using complications as pri-
mary outcome and assuming, based on this trial, that 50%
of patients with propofol will have a complication of at
least grade IIIa, 408 patients per group would be needed
to show a 20% relative reduction with a volatile anesthetic
with 80% power or 183 patients per group for a 30% rela-
tive reduction, respectively. Enrollment of up to 400 patients
to test our hypothesis would not have been possible.
In this context, it is important to point out that an effect
on clinical outcomes could be observed in the sevoflurane
group that was not significant because the study was not
powered to prove or disprove differences in secondary end-
points. In the sevoflurane group, hospital mortality (4.0% vs
8.3%) as well as major complication rates (grade lllb and
higher: 40% vs 50%) were decreased in comparison to the
propofol group. Also, EAD was lower in the sevoflurane
group (14% vs 23%). A study could certainly be powered in
the future to prove or disprove an effect by significance, but
it remains questionable if the observed effect size is large
enough to justify further investigations along these lines.
Strategies to reduce ischemia-reperfusion injury in trans-
plantation are of high interest because grafts are exposed
to a chain of injuries inducing ischemia starting from the
initial injury to the donor, over management of donors in
ICU settings to the procurement surgery and anesthesia, the
transport interval and condition, and finally the recipient
surgery. Various anesthetic regimens are nowadays used in
liver transplant recipients typically consisting either the use
of a modern volatile anesthetic, such as isoflurane, sevoflurane,
or desflurane, or the application of the intravenous anes-
thetic propofol or both. However, there is no higher level
evidence on what the best anesthetic agent in liver transplant
recipients is with respect to acute graft injury.30
Several previous trials have suggested that volatile anes-
thetics are organ protective in scenarios of organ ischemia
and reperfusion and might improve outcomes after cardiac
surgery.31 Interestingly, similar trials with volatile anes-
thetics have also been performed in liver resection surgery
where temporary clamping of the liver remnant may evoke
ischemic liver injury. Although some studies clearly showed
a benefit of volatile anesthetics,10,11,13 others did not.32 We
therefore designed an RCT to test the effect of volatile
anesthetics in liver transplantation, a situation of ischemia-
reperfusion. However, our hypothesis that the transplanted
liver endures less acute injury by sevoflurane postconditioning
could not be confirmed.
There are at least 2 possible explanations for this observa-
tion. The first explanation suggests that our regimen did not
have an effect because it was not properly applied. A recently
published study showed that preconditioning with volatile
anesthetics in the donor has a positive impact on outcomes.33
In our study, the transplanted graft was not exposed to vol-
atile anesthetics before cross-clamping in the donor because
the logistic effort to consent recipients of multiple organs
to a randomized anesthetic regiment in donors was felt to
be unsurmountable by our teams. Hence, it was not possi-
ble to perform preconditioning of graft in this study.
The second explanation is supported by the fact that
organ injury in transplantation is caused by a broad variety
of factors from organ procurement to preservation and graft
implantation. These include donor factors (e.g., age, race,
cause of death, summarized as donor risk index34), recipient-
specific factors (e.g., co-morbidities, severity of liver disease,
reflected in the MELD score21), and not at least procedure-
related, time (duration of ischemia) as well as immunological
factors which might cause graft injury. An effect by a subtle
intervention impacting positively on ischemia-reperfusion
might be lost in the noise of multiple lines of severe injury
to the graft and several hours of warm and cold ischemia.
This latter conclusion could explain the nonsignificant
effects we observed in favor of the sevoflurane group.
In conclusion, this first multicenter RCT evaluating a vol-
atile anesthetic in liver transplantation recipients failed to
show protection from acute organ injury in liver transplan-
tation. Less severe complications and EAD were found in
recipients with sevoflurane anesthesia, which suggests an
effect that cannot be established beyond doubt in this trial,
but might warrant further investigation.
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